Erasca
Erasca
One-line summary: Clinical-stage RAS/RAF-focused oncology biotech (NASDAQ: ERAS); tracked here for improving pancreatic-cancer RAF data plus a ~$500M raise (upsized to ~$600M) that the panel reads as a conviction/market-health signal in an otherwise dodgy biotech tape.
What it is
Erasca develops small-molecule inhibitors targeting the RAS/MAPK pathway, with a lead RAF program in pancreatic cancer. It sits in the same high-value Pan-RAS/RAF oncology space as Revolution Medicines, with which it has an IP dispute.
Why it matters to stock-market
Erasca is a two-signal name: (1) its RAF data is improving on longer follow-up and more patients — rare and bullish (data usually deteriorates) — with ORR moving "meaningfully into the range" seen from Revolution Medicines; (2) sam-facelli reads the successful upsized raise as a market-confidence tell in a weak biotech backdrop. Fits the RAS/RAF oncology re-rating theme adjacent to us-biotech-strategic-technology-offshoring's RVMD node.
Key facts
- RAF data improved + ~$500M raise (upsized ~$600M). sam-facelli in 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026: "the 500 million raise, which was upsized to about 600 something... in a market that was looking a bit dodgy... sounds like a sign of somebody believes in this. With the data improved relative to an addition of four more patients and a month more of follow up... the ORR is beginning to... get very meaningfully in the range that you see from Revolution."
- RevMed IP overhang. Skepticism about "where the drug came from"; Revolution Medicines "helps fan that conversation," with legal discussions (not yet litigated) about whether Erasca's drug infringes Revolution's IP. From 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026.
- Catalyst-rich. "A whole bunch more catalysts coming in the next few months" in pancreatic cancer.
Open questions
- Does the lower reported AE rate reflect a genuinely better tolerability profile or a management/definitional artifact (sam-facelli flags the ambiguity)?
- Does the RevMed IP dispute escalate to litigation and cap the equity?
Sources
Related
- us-biotech-strategic-technology-offshoring — the RVMD Pan-RAS oncology node this sits adjacent to